Karl Yen

ORCID: 0009-0002-2337-2045

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation”.

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation

UNC Libraries(2020)10.17615/fm1q-nk97

N/A

0DataRank · unranked

31 citations

Michael W. Konstan, Steven M. Rowe, Manfred Ballmann, Laurent Vernillet, Jordan Dunitz +25 more

Amlitelimab Reduces Th2-, Th1-, and Th17/22-Related Cytokines and Chemokines in Adults With Moderate-to-Severe Atopic Dermatitis: Results From an Exploratory Analysis of the Phase 2b STREAM-AD Study

SKIN The Journal of Cutaneous Medicine(2025)10.25251/x2k3y515

N/A

0DataRank · unranked

0 citations

Stephan Weidinger, Saeko Nakajima, Donald Y.M. Leung, Charles Lynde, Karl Yen +4 more